FOXO3a and the MAPK P38 Are Activated by Cetuximab to Induce Cell Death and Inhibit Cell Proliferation and Their Expression Predicts Cetuximab Efficacy in Colorectal Cancer

Overview

Journal Br J Cancer

Specialty Oncology

Date 2016 Sep 30

PMID 27685445

Citations 30

Authors

L Marzi

E Combes

N Vie

A Ayrolles-Torro

D Tosi

D Desigaud

E Perez-Gracia

C Larbouret

C Montagut

M Iglesias

M Jarlier

V Denis

L K Linares

E W-F Lam

P Martineau

M Del Rio

C Gongora

Affiliations

Soon will be listed here.

Abstract

Background: Cetuximab, a monoclonal antibody against EGFR used for the treatment of colorectal cancer (CRC), is ineffective in many patients. The aim of this study was to identify the signalling pathways activated by cetuximab in CRC cells and define new biomarker of response.

Methods: We used in vitro, in vivo models and clinical CRC samples to assess the role of p38 and FOXO3a in cetuximab mechanism of action.

Results: We show that cetuximab activates the MAPK p38. Specifically, p38 inhibition reduced cetuximab efficacy on cell growth and cell death. At the molecular level, cetuximab activates the transcription factor FOXO3a and promotes its nuclear translocation via p38-mediated phosphorylation, leading to the upregulation of its target genes p27 and BIM and the subsequent induction of apoptosis and inhibition of cell proliferation. Finally, we found that high FOXO3a and p38 expression levels are associated with better response rate and improved outcome in cetuximab-treated patients with CRC harbouring WT KRAS.

Conclusions: We identify FOXO3a as a key mediator of cetuximab mechanism of action in CRC cells and define p38 as its activator in this context. Moreover, high FOXO3a and p38 expression could predict the response to cetuximab in patients with CRC harbouring WT KRAS.

Citing Articles

Impact of synthesis methods on the functionality of antibody-conjugated gold nanoparticles for targeted therapy.

Anaki A, Tzror-Azankot C, Motiei M, Sadan T, Popovtzer R Nanoscale Adv. 2024; .

PMID: 39247853 PMC: 11372556. DOI: 10.1039/d4na00134f.

Developing a novel neutralizing monoclonal antibody against TrkB.

Yildirim G, Yilmaz E 3 Biotech. 2024; 14(10):221.

PMID: 39247456 PMC: 11377376. DOI: 10.1007/s13205-024-04063-x.

Activation of p38 and JNK by ROS Contributes to Deoxybouvardin-Mediated Intrinsic Apoptosis in Oxaliplatin-Sensitive and -Resistant Colorectal Cancer Cells.

Seo S, Joo S, Lee S, Yoon G, Cho S, Choi Y Antioxidants (Basel). 2024; 13(7).

PMID: 39061934 PMC: 11273932. DOI: 10.3390/antiox13070866.

FOXO3a-interacting proteins' involvement in cancer: a review.

Dong Z, Guo Z, Li H, Han D, Xie W, Cui S Mol Biol Rep. 2024; 51(1):196.

PMID: 38270719 DOI: 10.1007/s11033-023-09121-w.

Title Expression of FOXO3 and MAPK1 Genes in Patients with Benign Salivary Gland Tumors.

Kolary-Siekierska K, Niewiadomski P, Namiecinski W, Milonski J J Clin Med. 2024; 13(1).

PMID: 38202222 PMC: 10779754. DOI: 10.3390/jcm13010215.

References

Montagut C, Dalmases A, Bellosillo B, Crespo M, Pairet S, Iglesias M . Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med. 2012; 18(2):221-3. DOI: 10.1038/nm.2609. View

Krol J, Francis R, Albergaria A, Sunters A, Polychronis A, Coombes R . The transcription factor FOXO3a is a crucial cellular target of gefitinib (Iressa) in breast cancer cells. Mol Cancer Ther. 2007; 6(12 Pt 1):3169-79. DOI: 10.1158/1535-7163.MCT-07-0507. View

Sadanandam A, Lyssiotis C, Homicsko K, Collisson E, Gibb W, Wullschleger S . A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med. 2013; 19(5):619-25. PMC: 3774607. DOI: 10.1038/nm.3175. View

Liu H, Hu H, Chao J . Oxaliplatin down-regulates survivin by p38 MAP kinase and proteasome in human colon cancer cells. Chem Biol Interact. 2010; 188(3):535-45. DOI: 10.1016/j.cbi.2010.08.001. View

Real P, Benito A, Cuevas J, Berciano M, de Juan A, Coffer P . Blockade of epidermal growth factor receptors chemosensitizes breast cancer cells through up-regulation of Bnip3L. Cancer Res. 2005; 65(18):8151-7. DOI: 10.1158/0008-5472.CAN-05-1134. View

Hegde P, Rusnak D, Bertiaux M, Alligood K, Strum J, Gagnon R . Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles. Mol Cancer Ther. 2007; 6(5):1629-40. DOI: 10.1158/1535-7163.MCT-05-0399. View

Roy S, Srivastava R, Shankar S . Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer. J Mol Signal. 2010; 5:10. PMC: 2915986. DOI: 10.1186/1750-2187-5-10. View

Amado R, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman D . Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008; 26(10):1626-34. DOI: 10.1200/JCO.2007.14.7116. View

Khambata-Ford S, Garrett C, Meropol N, Basik M, Harbison C, Wu S . Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol. 2007; 25(22):3230-7. DOI: 10.1200/JCO.2006.10.5437. View

10.

Chiu S, Chao J, Lee Y, Hsu T . Regulation of gamma-H2AX and securin contribute to apoptosis by oxaliplatin via a p38 mitogen-activated protein kinase-dependent pathway in human colorectal cancer cells. Toxicol Lett. 2008; 179(2):63-70. DOI: 10.1016/j.toxlet.2008.04.004. View

11.

Germani A, Matrone A, Grossi V, Peserico A, Sanese P, Liuzzi M . Targeted therapy against chemoresistant colorectal cancers: Inhibition of p38α modulates the effect of cisplatin in vitro and in vivo through the tumor suppressor FoxO3A. Cancer Lett. 2013; 344(1):110-118. DOI: 10.1016/j.canlet.2013.10.035. View

12.

Gongora C, Candeil L, Vezzio N, Copois V, Denis V, Breil C . Altered expression of cell proliferation-related and interferon-stimulated genes in colon cancer cells resistant to SN38. Cancer Biol Ther. 2008; 7(6):822-32. DOI: 10.4161/cbt.7.6.5838. View

13.

Roepman P, Schlicker A, Tabernero J, Majewski I, Tian S, Moreno V . Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. Int J Cancer. 2013; 134(3):552-62. PMC: 4234005. DOI: 10.1002/ijc.28387. View

14.

Chiacchiera F, Grossi V, Cappellari M, Peserico A, Simonatto M, Germani A . Blocking p38/ERK crosstalk affects colorectal cancer growth by inducing apoptosis in vitro and in preclinical mouse models. Cancer Lett. 2012; 324(1):98-108. DOI: 10.1016/j.canlet.2012.05.006. View

15.

Zarubin T, Han J . Activation and signaling of the p38 MAP kinase pathway. Cell Res. 2005; 15(1):11-8. DOI: 10.1038/sj.cr.7290257. View

16.

Wilson K, Fitzgibbon M, Caron P, Griffith J, Chen W, McCaffrey P . Crystal structure of p38 mitogen-activated protein kinase. J Biol Chem. 1996; 271(44):27696-700. DOI: 10.1074/jbc.271.44.27696. View

17.

Marisa L, De Reynies A, Duval A, Selves J, Gaub M, Vescovo L . Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med. 2013; 10(5):e1001453. PMC: 3660251. DOI: 10.1371/journal.pmed.1001453. View

18.

Takeuchi K, Shin-ya T, Nishio K, Ito F . Mitogen-activated protein kinase phosphatase-1 modulated JNK activation is critical for apoptosis induced by inhibitor of epidermal growth factor receptor-tyrosine kinase. FEBS J. 2009; 276(5):1255-65. DOI: 10.1111/j.1742-4658.2008.06861.x. View

19.

Grossi V, Liuzzi M, Murzilli S, Martelli N, Napoli A, Ingravallo G . Sorafenib inhibits p38α activity in colorectal cancer cells and synergizes with the DFG-in inhibitor SB202190 to increase apoptotic response. Cancer Biol Ther. 2012; 13(14):1471-81. PMC: 3542239. DOI: 10.4161/cbt.22254. View

20.

Candeil L, Gourdier I, Peyron D, Vezzio N, Copois V, Bibeau F . ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases. Int J Cancer. 2004; 109(6):848-54. DOI: 10.1002/ijc.20032. View